Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $152.2 million.

  • Vanda Pharmaceuticals' Total Non-Current Liabilities rose 4086.02% to $152.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $152.2 million, marking a year-over-year increase of 4086.02%. This contributed to the annual value of $152.2 million for FY2025, which is 4086.02% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Total Non-Current Liabilities of $152.2 million as of Q4 2025, which was up 4086.02% from $124.1 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $152.2 million during Q4 2025, with a 5-year trough of $72.9 million in Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $99.8 million (2024), whereas its average is $101.3 million.
  • In the last 5 years, Vanda Pharmaceuticals' Total Non-Current Liabilities plummeted by 907.85% in 2023 and then surged by 4086.02% in 2025.
  • Vanda Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $84.5 million in 2021, then grew by 18.67% to $100.2 million in 2022, then decreased by 5.53% to $94.7 million in 2023, then grew by 14.12% to $108.1 million in 2024, then soared by 40.86% to $152.2 million in 2025.
  • Its Total Non-Current Liabilities stands at $152.2 million for Q4 2025, versus $124.1 million for Q3 2025 and $128.4 million for Q2 2025.